Clinical trial
Vaccine Therapy in Treating Patients With Advanced Cancer
NCT00004881 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004881 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Advanced Cancer |
| Official title | Phase I Bridging Trial of TG4010 as Antigen-Specific Immunotherapy in Patients With MUC-1 Positive Advanced Cancer |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | MVA-MUC1-IL2 vaccine |
| Start date | Apr 1, 2000 |
| Completion | May 1, 2004 |
| First posted | May 25, 2004 |
| Last update posted | Jun 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: